Treatment of essential hypertension: The recommendation dose is 40 mg once daily. In cases where the target blood pressure is not achieved, telmisartan dose can be increased to a maximum of 80 mg once daily. Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan. When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment.
In patients with severe hypertension treatment with telmisartan at doses up to 160 mg alone and in combination with hydrochlorothiazide 12.5 - 25 mg was daily was well tolerated and effective.
Cardiovascular prevention: The recommended dose of Telmisartan tablet is 80 mg once daily and can be administered with or without food. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing cardiovascular morbidity and mortality.
When initiating Telmisartan tablet therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate adjustment of medications that lower blood pressure may be necessary.
Telmisartan tablet may be taken with or without food.
Special populations: Renal impairment: No posology adjustment is required for patients with renal impairment, including those on haemodialysis. Telmisartan is not removed from blood by hemofiltration.
Hepatic impairment: In patients with mild to moderate hepatic impairment the posology should not exceed 40 mg once daily.
Elderly patients: No dose adjustment is necessary.
Children and adolescents: The safety and efficacy of Telmisartan tablet for use in children below 18 years have not been established.
Method of administration: Telmisartan tablets may be taken with or without food.
Route of Administration: Oral.